Usefulness of the Hepatitis C Virus Core Antigen Assay for Screening of a Population Undergoing Routine Medical Checkup

Gaudy, Catherine; Thevenas, Catherine; Tichet, Jean; Mariotte, N.; Goudeau, Alain; Dubois, Frédéric

doi:10.1128/jcm.43.4.1722-1726.2005

Cited by 34 publications

(24 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies have observed a very good correlation (0.72 Ͻ r Ͻ 0.80) between quantification methods of HCV RNA and HCV CA in HCV-monoinfected patients (7,12,20,22,24). In HCV/HIV-coinfected patients, we also found an excellent correlation at baseline between these two markers of HCV infection (0.92).…”

Section: Discussionsupporting

confidence: 63%

Comparison of Serum Hepatitis C Virus (HCV) RNA and Core Antigen Levels in Patients Coinfected with Human Immunodeficiency Virus and HCV and Treated with Interferon plus Ribavirin

et al. 2006

View full text Add to dashboard Cite

Trak-C (Ortho-ClinicalToday, RNA detection and quantification are the only systems for pretherapeutic and therapeutic follow-up of hepatitis C virus (HCV)-infected persons undergoing treatment (4,6,8,11,17,23). Measures of HCV RNA before treatment and at 12 weeks of treatment are used to determine early decrease of viral load during treatment. A 2-log HCV RNA variation is considered a reference for management of treatment for HCV-infected persons (1, 14). Since RNA detection is laborintensive and very expensive, many laboratories have sought to replace HCV RNA detection or quantification by other markers. Moreover, HCV core antigen (CA) is more stable than HCV RNA and needs no particular precautions for preparation and sample storage (21). Several kits for detection of HCV CA have recently been developed and commercialized (19). Methods for detecting HCV CA using monoclonal antibody to HCV CA were also developed, such as the Trak-C assay, developed by Ortho-Clinical Diagnostics and commercialized in 2003 (21). However, the low sensitivity of this assay needs to be evaluated in pretherapeutic and therapeutic follow-up of HCV-infected patients. This enzyme-linked immunosorbent assay (ELISA)-based method has already been demonstrated with HCV-infected patients as a new diagnosis marker for HCV infection, with an excellent correlation observed for all studies (9,12,21,22,24,25).The framework of the ANRS HC02 RIBAVIC protocol included 412 human immunodeficiency virus (HIV)/HCVcoinfected patients and demonstrated the efficacy and safety of the anti-HCV combined interferon (IFN)-ribavirin therapy (3). In this study, viral factors of treatment response prediction were identified: a baseline viremia below 5.7 log 10 IU/ml and genotypes 2, 3, and 5 (as reported by others [2,5]).Therefore, we have evaluated the usefulness of the new HCV CA assay (Trak-C assay; Ortho-Clinical Diagnostics) in comparison with the HCV RNA load for therapeutic follow-up of HIV/HCV-coinfected patients included in the ANRS HC02 RIBAVIC study. We have shown that the HCV CA assay assessed virological response similarly to the HCV RNA assay and had a good predictive value of nonresponse to combination therapy.

show abstract

Section: Discussionsupporting

confidence: 63%

Comparison of Serum Hepatitis C Virus (HCV) RNA and Core Antigen Levels in Patients Coinfected with Human Immunodeficiency Virus and HCV and Treated with Interferon plus Ribavirin

et al. 2006

View full text Add to dashboard Cite

show abstract

“…The importance of HCVcoreAg in the early diagnosis of HCV infection has been established in many studies (25)(26)(27). Also, the monitoring of HCVcoreAg during the treatment course can help to predict responses to anti-viral therapy (28,29).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Hepatitis C Virus Infection in Antibody Positive Orphan Newborns

Ziyaeyan

Jamalidoust

Moeini

2012

Jundishapur J Microbiol

View full text Add to dashboard Cite

Comparing diagnostic methods of vertical transmission of HCV infection can serve as a cornerstone for better understanding of the capability of each methods in more accurate diagnosis of HCV infection in the newborns.HCV is spread through contaminated blood and blood products with percutaneous exposure. This disease also poses a risk to injection drug users (IDU) and hemodialysis patients. However, sexual transmission of HCV is comparably low in Iran, and in addition the risk through occupational exposure is also very low. Mother-to-infant transmission rates vary widely (5-9). Usually, a mother BackgroundHepatitis C virus (HCV) infection is a major cause of; chronic hepatitis, liver cirrhosis and liver cancer. It represents an enormous global health problem, affecting 130-170 million people worldwide. In Iran, the prevalence of HCV in the general population is 0.5% (1), but the rate is higher in certain at risk populations (2-4).Background: The rate of mother-to-infant hepatitis C virus (HCV) transmission is relatively low, however, this mode of infection is the most important route for childhood HCV involvement. The chances of transmission are increased by the level of maternal HCV viraemia and maternal human immunodeficiency virus (HIV) co infection. Objectives: The objective of the present study was to determine the presence of HCV infection in orphan newborns of infected mothers. Patients and Methods: A total of 29, two to seven month old, orphan infants were included in the study. The tests performed consisted of the detection of; anti-HCV and anti-HIV antibodies, HCV RNA in the plasma and peripheral blood mononuclear cells by realtime polymerase chain reaction (PCR), and finally the detection of HCV core antigens (HCV core Ag). Results: Anti-HCV antibodies were detectable in all of the infants. However HCV RNA was undetectable in both plasma and peripheral blood mononuclear cells (PBMCs) and there were also no anti-HIV 1/2 antibodies present in the infants. Conclusions: Few studies have addressed the issue of mother-to-infant transmission of HCV among orphan newborns. According to the present study, carried out with orphan babies, the use of a HCV core Ag assay and evaluation of HCV RNA in PBMCs together with HCV RNA real-time PCR on the plasma, could benefit the prediction or exclusion of HCV transmission from mother to child.

show abstract

“…Detection of antibodies has some limitations, such as lack of antibodies during the early stage of infection and in immunodeficient patients, thereby leading to false-negative results (2). It is difficult to generate high-quality antibodies against core protein, although detection of HCV core antigen present in serum is highly sensitive and specific (3).…”

mentioning

confidence: 99%

Inhibition of Hepatitis C Virus Production by Aptamers against the Core Protein

Shi

Gao

et al. 2014

J Virol

View full text Add to dashboard Cite

bHepatitis C virus (HCV) core protein is essential for virus assembly. HCV core protein was expressed and purified. Aptamers against core protein were raised through the selective evolution of ligands by the exponential enrichment approach. Detection of HCV infection by core aptamers and the antiviral activities of aptamers were characterized. The mechanism of their anti-HCV activity was determined. The data showed that selected aptamers against core specifically recognize the recombinant core protein but also can detect serum samples from hepatitis C patients. Aptamers have no effect on HCV RNA replication in the infectious cell culture system. However, the aptamers inhibit the production of infectious virus particles. Beta interferon (IFN-␤) and interferon-stimulated genes (ISGs) are not induced in virally infected hepatocytes by aptamers. Domains I and II of core protein are involved in the inhibition of infectious virus production by the aptamers. V31A within core is the major resistance mutation identified. Further study shows that the aptamers disrupt the localization of core with lipid droplets and NS5A and perturb the association of core protein with viral RNA. The data suggest that aptamers against HCV core protein inhibit infectious virus production by disrupting the localization of core with lipid droplets and NS5A and preventing the association of core protein with viral RNA. The aptamers for core protein may be used to understand the mechanisms of virus assembly. Core-specific aptamers may hold promise for development as early diagnostic reagents and potential therapeutic agents for chronic hepatitis C.

show abstract

Usefulness of the Hepatitis C Virus Core Antigen Assay for Screening of a Population Undergoing Routine Medical Checkup

Cited by 34 publications

References 18 publications

Comparison of Serum Hepatitis C Virus (HCV) RNA and Core Antigen Levels in Patients Coinfected with Human Immunodeficiency Virus and HCV and Treated with Interferon plus Ribavirin

Comparison of Serum Hepatitis C Virus (HCV) RNA and Core Antigen Levels in Patients Coinfected with Human Immunodeficiency Virus and HCV and Treated with Interferon plus Ribavirin

Evaluation of Hepatitis C Virus Infection in Antibody Positive Orphan Newborns

Inhibition of Hepatitis C Virus Production by Aptamers against the Core Protein

Contact Info

Product

Resources

About